Evidence map›Paper›PMID 42209515›Full record

ReviewNature reviews. Disease primers2026

Osteomyelitis.

Sandra R Arnold, Vincenzo Giordano, William T Obremskey, Edward M Schwarz, Mark S Smeltzer, Deborah J Veis, James E Cassat

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra R ArnoldDepartment of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA.
Vincenzo GiordanoServiço de Ortopedia e Traumatologia Prof. Nova Monteiro-Hospital Municipal Miguel Couto, Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.
William T ObremskeyDepartment of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Edward M SchwarzDepartment of Orthopedics, University of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-4854-9698
Mark S SmeltzerDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Deborah J VeisDepartment of Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-7101-5582
James E CassatDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. jim.cassat@vumc.org.ORCID http://orcid.org/0000-0002-1199-1167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteomyelitis, defined as inflammation of bone, is a highly morbid disease that is most commonly caused by bacterial infection. Infectious osteomyelitis occurs across a spectrum of ages and affects previously healthy individuals as well as individuals with medical comorbidities. Establishment of osteomyelitis typically occurs following one of three general pathological mechanisms, including haematogenous seeding of healthy or injured bone, extension of a contiguous soft tissue infection, or direct inoculation of microorganisms into the bone following trauma. A wide spectrum of microbial pathogens can cause osteomyelitis in these settings. The most common aetiologies share common pathogenic traits such as the propensity to form biofilms, the elaboration of immunoevasive toxins and virulence factors, and the ability to adhere to and invade bone tissue. Challenges in diagnosing, prognosing and treating osteomyelitis remain owing to limitations of conventional cultures, absence of faithful biomarkers, inability to delineate acute versus chronic infection, and therapeutic recalcitrance. Despite prolonged antimicrobial therapy, many individuals with osteomyelitis fail treatment and go on to develop highly morbid complications. Improvements in the management of osteomyelitis will require an ongoing commitment to multidisciplinary clinical care, basic and translational research to uncover pathophysiological mechanisms of disease, and sustained investments in new approaches for the diagnosis, treatment and mitigation of complications.

Indexed as

OsteomyelitisAnti-Bacterial AgentsBiofilmsHumansAnti-Bacterial Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.